Assisted Reproductive Technology Outcomes in Women with Normal Ovarian Response Receiving Recombinant Luteinizing Hormone/Human Menopausal Gonadotropin: An Observational Study
DOI: https://doi.org/10.2147/ijwh.s454410
2024-06-15
International Journal of Women s Health
Abstract:Yingxiu Liang, 1 Xiaohong Hou, 1 Haoying Chen, 1 Ruqing Yang, 1 Ruina Wang, 1 Ruotong Mao, 1 Junzhao Zhao, 1 Hui Chen, 2 Jing Cheng 1 1 Reproductive Center, Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325088, People's Republic of China; 2 School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, New South Wales, 2007, Australia Correspondence: Jing Cheng, Reproductive Center, Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, No. 306 Hualongqiao Road, Lucheng District, Wenzhou, Zhejiang Province, 325088, People's Republic of China, Tel +86 13780193700, Fax +86 57788002304, Email Hui Chen, Faculty of Science, University of Technology Sydney, No. 15 of Broadway, Ultimo, New South Wales, 2007, Australia, Tel/Fax +61 295141328, Email Objective: Additive human menopausal gonadotropin (HMG)/recombinant luteinizing hormone (r-LH) to follicle-stimulating hormone (FSH) can improve pregnancy outcomes in patients with poor ovarian response during assisted reproductive procedures. However, their effects on patients with normal ovarian response during such procedures are unclear, which formed the aim of this study. Methods: This retrospective study enrolled 456 infertile women who underwent in vitro fertilization or intracytoplasmic sperm injection treatment. Group 1 received FSH; Group 2 received FSH+HMG/r-LH; Group 3 received FSH+HMG+r-LH. Results: The age and Body Mass Index were significantly greater in Group III. The endometrial thickness was greater in Groups II and III, suggesting better endometrial receptivity. Better pregnancy and birth outcomes were seen in Group 3. In sub-cohorts of women older than 32 years old or with overweight/obesity, pregnancy and birth outcomes were also much better in Group 3, albeit without statistical significance. Conclusion: The addition of both HMG and r-LH to FSH may improve the chance of infertile women with normal ovarian responses to have more success in having live birth babies, specifically in those over 32 years of age or with overweight/obese patients who typically face challenges in conceiving and sustaining a pregnancy. Keywords: in vitro fertilization, intracytoplasmic sperm injection, live birth rate, cumulative live birth rate Infertility affects approximately 15% of couples worldwide, 1 who can achieve pregnancy via assisted reproduction techniques. In patients with a normal ovarian response, the prolonged gonadotropin-releasing hormone agonist (GnRH-a) protocol is the most commonly used protocol for in vitro fertilization-embryo transfer (IVF-ET) procedure. 2,3 However, GnRH-a may lead to over-suppression of luteinizing hormone (LH), negatively impacting IVF-ET outcome. 4 Optimal LH activity is critical for the quality and function of oocytes, 5 and cell proliferation and cytoplasmic maturation of oocytes. 6 During ovarian stimulation, LH administration varies in dose and timing. 7 Nevertheless, adding LH to follicle-stimulating hormone (FSH) can improve ovarian function in patients with a poor ovarian response, 8 by increasing the mature egg rate, embryo quality, 9 and implantation rate. 10 Additive recombinant (r)-LH during controlled ovarian stimulation can obtain >5 oocytes. 11 In women aged >35 years, LH supplementation can improve clinical pregnancy and ongoing pregnancy rates. 8 Before r-LH was available, human menopausal gonadotropin (HMG) was once the only option for stimulating LH activity, 12 which significantly improved clinical pregnancy rates than FSH alone in women with normal gonadotropic responses. 13 When using the GnRH-antagonist protocol, r-LH seemed to result in a higher cumulative live birth rate than HMG. 14 However, when using the early-follicular phase prolonged GnRH-a protocol, the optimal choice between r-LH, HMG, or combined is unclear for women with normal ovarian response. Herein, we explored the pregnancy outcomes and medical costs in women with normal ovarian response who received various early-follicular phase prolonged GnRH-a protocols. In the retrospective observational study, women who received IVF or ICSI treatments with early-follicular phase prolonged GnRH-a protocols were included from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University between February 1, 2021 and March 31, 2022. This research was conducted in accordance w -Abstract Truncated-
obstetrics & gynecology